Lipid Modified with Pyridinium Betaine Manipulates Liposomal Membrane Fusion Behavior for Spatially Confined Cytoplasmic Delivery

Read full text
Authors: Huijuan Zheng, Chunxiong Zheng, Yongkang Du, Xiaobing Lin, Yingting Zhao, Ke Wang, TINGHUA LÜ, Huanyu Xiong, Jiadong Zhou, Bingjia Xu, Mingqiang Li, Guang Shi
Cited by: 2
References: 26

Abstract

Spatially confining the membrane-fusion effects of fusogenic delivery systems in tumors can enhance therapeutic efficacy and reduce systemic toxicity. However, current existing fusion-regulating strategies often suffer from insensitivity and unidirectional control, leading to suboptimal antitumor effects and potential safety risks. Here, we designed a pyridinium betaine-capped lipid, 2-(4-((2,3-di(stearoyloxy)propyl)carbamoyl)pyridin-1-ium-1-yl)acetate (DSPCPA)), as a pH-responsive regulator to precisely manipulate the membrane-fusion behavior of fusogenic liposomes. Incorporating DSPCPA, we optimized a formulation of self-adaptive, environment-responsive fusogenic liposome (SENDFUL) capable of rapidly and reversibly switching membrane-fusion activity responding acidic tumor microenvironments. At physiological pH, SENDFUL remains negatively-charged due to the zwitterionic nature of DSPCPA, undergoing in a non-fusogenic state. In acidic tumor regions (pH 6.5), protonation of DSPCPA rapidly converts surface charge to positive, triggering tumor-specific fusion via strengthened electrostatic interactions with cellular membranes. This reversible transition highly confines lysosome-bypassing cytosolic delivery to tumors, minimizing systemic toxicity. We utilized SENDFUL to construct a nanoagonist for the stimulator of interferon genes (STING) pathway, which elicited potent antitumor immunity with negligible toxicity in vitro and in vivo. Thus, SENDFUL represents an advanced strategy for spatially precise regulation of liposomal membrane fusion, providing a safe and efficient platform for tumor-specific intracellular drug delivery.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics RNA Interference and Gene Delivery Cancer Research and Treatments

Publication details

Journal / source
Angewandte Chemie International Edition
Publisher
Wiley
Volume
65
Issue
21
Pages
e22025–e22025
Publication date
12 February 2026
Language
EN